Index RUT P/E - EPS (ttm) -0.29 Insider Own 3.86% Shs Outstand 232.45M Perf Week 35.83%
Market Cap 2.03B Forward P/E 74.86 EPS next Y 0.12 Insider Trans -6.38% Shs Float 223.70M Perf Month 21.79%
Income -65.81M PEG - EPS next Q -0.12 Inst Own 59.52% Short Float 15.17% Perf Quarter -1.91%
Sales 159.11M P/S 12.75 EPS this Y -29.90% Inst Trans 50.07% Short Ratio 6.08 Perf Half Y 121.32%
Book/sh 0.64 P/B 13.52 EPS next Y 129.89% ROA -23.53% Short Interest 33.93M Perf Year 86.32%
Cash/sh 0.87 P/C 10.02 EPS next 5Y 30.00% ROE -47.64% 52W Range 3.16 - 10.13 Perf YTD 40.65%
Dividend Est. - P/FCF - EPS past 5Y 28.61% ROI -26.17% 52W High -13.92% Beta 0.78
Dividend TTM - Quick Ratio 4.36 Sales past 5Y 146.90% Gross Margin 83.09% 52W Low 175.95% ATR (14) 0.50
Dividend Ex-Date - Current Ratio 4.53 EPS Y/Y TTM 27.62% Oper. Margin -38.90% RSI (14) 73.70 Volatility 7.52% 5.78%
Employees 267 Debt/Eq 0.70 Sales Y/Y TTM 152.32% Profit Margin -41.36% Recom 1.00 Target Price 13.72
Option/Short Yes / Yes LT Debt/Eq 0.67 EPS Q/Q 11.99% Payout - Rel Volume 4.42 Prev Close 6.79
Sales Surprise 26.44% EPS Surprise 25.37% Sales Q/Q 304.81% Earnings May 02 AMC Avg Volume 5.58M Price 8.72
SMA20 29.33% SMA50 13.19% SMA200 48.24% Trades
Volume 24,638,617 Change 28.42%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-05-24 Initiated Leerink Partners
Outperform
$14
Dec-18-23 Initiated Raymond James
Strong Buy
$12
Sep-07-23 Initiated H.C. Wainwright
Buy
$9
Aug-25-23 Upgrade Cantor Fitzgerald
Neutral → Overweight
$5 → $10
Mar-03-23 Upgrade Wedbush
Neutral → Outperform
$3 → $6
Nov-17-22 Upgrade Piper Sandler
Neutral → Overweight
$3 → $8
May-06-22 Downgrade Cantor Fitzgerald
Overweight → Neutral
$7 → $1
Dec-01-21 Upgrade Ladenburg Thalmann
Neutral → Buy
$6
Oct-14-21 Downgrade Ladenburg Thalmann
Buy → Neutral
Jul-21-21 Downgrade Jefferies
Buy → Hold
$11 → $2
Jul-20-21 Downgrade Wedbush
Outperform → Neutral
$3
Jul-20-21 Downgrade Piper Sandler
Overweight → Neutral
$14 → $4
Mar-23-21 Initiated Wedbush
Outperform
$14
Jan-06-21 Initiated Cantor Fitzgerald
Overweight
$14
Oct-20-20 Resumed Citigroup
Buy
$13
Feb-18-20 Resumed Jefferies
Buy
$11
Feb-12-20 Initiated Citigroup
Buy
$13
Feb-10-20 Initiated Cowen
Outperform
Apr-08-19 Initiated Piper Jaffray
Overweight
$15
Aug-24-18 Initiated Jefferies
Buy
$7
Show Previous Ratings
May-03-24 02:16PM
09:57AM
07:31AM
06:21AM
(Thomson Reuters StreetEvents)
May-02-24 08:58PM
05:45PM
Loading…
05:45PM
04:47PM
(Associated Press Finance)
04:02PM
May-01-24 08:00AM
Apr-25-24 10:02AM
Apr-18-24 08:00AM
Apr-02-24 11:34AM
Mar-28-24 04:05PM
Mar-25-24 08:00AM
Mar-16-24 06:00PM
04:35PM
Loading…
Mar-12-24 04:35PM
Feb-28-24 05:40PM
Feb-27-24 08:00AM
06:10AM
Feb-23-24 10:16AM
Feb-22-24 06:00PM
05:15PM
04:45PM
04:26PM
(Associated Press Finance)
04:01PM
Feb-19-24 03:30PM
12:24PM
Feb-15-24 10:00AM
Feb-09-24 09:55AM
08:50AM
12:16PM
Loading…
Feb-08-24 12:16PM
12:00PM
09:40AM
Feb-07-24 09:34AM
Feb-06-24 04:00PM
Feb-02-24 02:15AM
Feb-01-24 08:00AM
Jan-29-24 12:35PM
Jan-12-24 07:56AM
Jan-10-24 02:27PM
Jan-08-24 08:00AM
Jan-03-24 08:03AM
Dec-29-23 11:01PM
Dec-20-23 08:00AM
Dec-14-23 06:40AM
Dec-05-23 09:11AM
Nov-21-23 04:02PM
09:37AM
08:01AM
Nov-17-23 09:00AM
Nov-15-23 04:02PM
Nov-13-23 04:02PM
Nov-10-23 08:05AM
Nov-06-23 08:00AM
Nov-03-23 08:00AM
Nov-02-23 09:40AM
Nov-01-23 10:42AM
Oct-31-23 11:15PM
(Thomson Reuters StreetEvents) +9.12%
05:09PM
08:40AM
07:29AM
(Associated Press Finance)
07:00AM
Oct-30-23 05:42PM
Oct-23-23 08:07AM
Oct-19-23 10:21AM
Oct-18-23 04:31PM
04:02PM
10:42AM
Oct-17-23 07:24PM
07:23PM
07:06PM
07:01PM
Oct-13-23 08:00AM
Oct-11-23 04:17PM
Oct-04-23 08:00AM
Sep-28-23 08:02AM
Sep-25-23 04:15AM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-11-23 08:00AM
Sep-08-23 08:00AM
Sep-07-23 08:00AM
Sep-06-23 12:36PM
12:13PM
Aug-30-23 01:02PM
Aug-28-23 10:22AM
Aug-26-23 03:17PM
Aug-25-23 09:42AM
Aug-24-23 11:05AM
Aug-17-23 09:31AM
Aug-07-23 02:34PM
Aug-04-23 08:29AM
Aug-03-23 08:26AM
Aug-02-23 08:35AM
07:26AM
07:00AM
Jul-27-23 04:05PM
Jul-26-23 07:55AM
Jul-20-23 04:05PM
Jul-16-23 09:37AM
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RAAB MICHAEL President & CEO Apr 29 '24 Option Exercise 0.99 30,000 29,700 1,340,933 May 01 07:59 PM RAAB MICHAEL President & CEO Apr 29 '24 Sale 6.40 30,000 192,057 1,310,933 May 01 07:59 PM RAAB MICHAEL President & CEO Apr 15 '24 Sale 7.06 7,500 52,924 1,310,933 Apr 17 04:20 PM RAAB MICHAEL President & CEO Apr 01 '24 Sale 7.31 1,518 11,097 1,318,433 Apr 02 04:05 PM GRAMMER ELIZABETH A See Remarks Mar 20 '24 Sale 7.73 86,000 664,978 312,993 Mar 22 04:42 PM Rosenbaum David P. Chief Development Officer Feb 26 '24 Sale 9.20 5,183 47,684 175,936 Feb 28 06:57 PM RAAB MICHAEL President & CEO Feb 20 '24 Sale 8.75 22,917 200,439 1,319,951 Feb 22 04:58 PM Rodriguez Susan Chief Commercial Officer Feb 20 '24 Sale 8.75 6,928 60,594 452,795 Feb 22 04:56 PM Renz Justin A Chief Financial Officer Feb 20 '24 Sale 8.75 5,341 46,714 304,835 Feb 22 05:01 PM Blanks Robert See Remarks Feb 20 '24 Sale 8.75 5,017 43,880 368,186 Feb 22 04:58 PM Rosenbaum David P. Chief Development Officer Feb 20 '24 Sale 8.75 5,017 43,880 378,985 Feb 22 06:30 PM Williams Laura A Chief Medical Officer Feb 20 '24 Sale 8.75 4,803 42,008 380,138 Feb 22 04:56 PM GRAMMER ELIZABETH A See Remarks Feb 20 '24 Sale 8.75 4,432 38,764 398,993 Feb 22 04:57 PM Felsch Robert Ora See Remarks Feb 20 '24 Sale 8.75 2,352 20,571 184,834 Feb 22 04:56 PM Rosenbaum David P. Chief Development Officer Feb 20 '24 Sale 8.75 2,294 20,064 181,119 Feb 22 06:30 PM Rosenbaum David P. Chief Development Officer Feb 08 '24 Sale 9.18 15,344 140,846 384,002 Feb 09 04:14 PM Rosenbaum David P. Chief Development Officer Jan 08 '24 Sale 6.64 30,000 199,200 286,596 Jan 10 05:36 PM Renz Justin A Chief Financial Officer Dec 26 '23 Option Exercise 0.99 75,000 74,250 407,426 Dec 28 05:44 PM Renz Justin A Chief Financial Officer Dec 26 '23 Sale 6.36 225,000 1,430,122 182,426 Dec 28 05:44 PM Rosenbaum David P. Chief Development Officer Dec 18 '23 Sale 6.07 5,675 34,447 316,596 Dec 20 04:49 PM Rosenbaum David P. Chief Development Officer Dec 14 '23 Sale 5.55 7,000 38,850 322,271 Dec 15 06:13 PM GRAMMER ELIZABETH A See Remarks Dec 11 '23 Sale 5.08 50,000 253,925 275,675 Dec 13 05:44 PM Rosenbaum David P. Chief Development Officer Dec 08 '23 Sale 5.27 20,000 105,476 329,271 Dec 08 05:58 PM Rosenbaum David P. Chief Development Officer Dec 05 '23 Sale 5.00 10,272 51,360 349,271 Dec 06 04:49 PM Rosenbaum David P. Chief Development Officer Nov 30 '23 Sale 4.50 3,000 13,500 359,543 Dec 01 04:47 PM RAAB MICHAEL President & CEO Nov 20 '23 Sale 4.36 11,368 49,589 867,868 Nov 22 05:19 PM Rodriguez Susan Chief Commercial Officer Nov 20 '23 Sale 4.36 4,714 20,563 346,973 Nov 22 05:20 PM Renz Justin A Chief Financial Officer Nov 20 '23 Sale 4.36 2,873 12,533 332,426 Nov 22 05:20 PM Blanks Robert See Remarks Nov 20 '23 Sale 4.36 2,835 12,367 260,453 Nov 22 05:17 PM Rosenbaum David P. Chief Development Officer Nov 20 '23 Sale 4.36 2,835 12,367 362,543 Nov 22 05:21 PM Williams Laura A Chief Medical Officer Nov 20 '23 Sale 4.36 2,581 11,259 266,191 Nov 22 05:22 PM GRAMMER ELIZABETH A See Remarks Nov 20 '23 Sale 4.36 2,384 10,399 325,675 Nov 22 05:19 PM Felsch Robert Ora See Remarks Nov 20 '23 Sale 4.36 1,044 4,554 117,066 Nov 22 05:18 PM Rosenbaum David P. Chief Development Officer Nov 20 '23 Sale 4.36 932 4,066 113,293 Nov 22 05:21 PM Williams Laura A Chief Medical Officer Nov 15 '23 Sale 4.00 25,000 99,998 266,839 Nov 17 05:30 PM Rosenbaum David P. Chief Development Officer Oct 10 '23 Sale 4.00 1,644 6,576 365,378 Oct 12 05:09 PM Rosenbaum David P. Chief Development Officer Sep 08 '23 Sale 4.55 2,897 13,181 367,022 Sep 12 05:24 PM RAAB MICHAEL President & CEO Aug 21 '23 Sale 3.55 11,419 40,558 876,236 Aug 23 04:41 PM Rodriguez Susan Chief Commercial Officer Aug 21 '23 Sale 3.55 4,733 16,811 348,687 Aug 23 04:48 PM Renz Justin A Chief Financial Officer Aug 21 '23 Sale 3.55 2,884 10,243 333,849 Aug 23 04:42 PM Rosenbaum David P. Chief Development Officer Aug 21 '23 Sale 3.55 2,846 10,108 369,919 Aug 23 04:45 PM Blanks Robert See Remarks Aug 21 '23 Sale 3.55 2,846 10,108 263,288 Aug 23 04:36 PM Williams Laura A Chief Medical Officer Aug 21 '23 Sale 3.55 2,591 9,203 291,839 Aug 23 04:46 PM GRAMMER ELIZABETH A See Remarks Aug 21 '23 Sale 3.55 2,392 8,496 328,059 Aug 23 04:39 PM Felsch Robert Ora See Remarks Aug 21 '23 Sale 3.55 1,048 3,722 115,110 Aug 23 04:38 PM Rosenbaum David P. Chief Development Officer Aug 21 '23 Sale 3.55 937 3,328 111,225 Aug 23 04:45 PM Williams Laura A Chief Medical Officer Jun 27 '23 Sale 3.35 25,000 83,632 294,430 Jun 29 07:22 PM Blanks Robert See Remarks Jun 23 '23 Option Exercise 3.42 33,333 113,999 299,467 Jun 27 06:40 PM Blanks Robert See Remarks Jun 23 '23 Sale 3.63 33,333 121,042 266,134 Jun 27 06:40 PM RAAB MICHAEL President & CEO May 23 '23 Sale 3.65 11,357 41,489 887,655 May 25 08:55 AM Rodriguez Susan Chief Commercial Officer May 23 '23 Sale 3.65 4,711 17,210 353,420 May 25 08:52 AM Renz Justin A Chief Financial Officer May 23 '23 Sale 3.65 2,873 10,496 336,733 May 25 08:53 AM Blanks Robert See Remarks May 23 '23 Sale 3.65 2,835 10,357 266,134 May 25 08:54 AM Rosenbaum David P. Chief Development Officer May 23 '23 Sale 3.65 2,835 10,357 372,765 May 25 08:52 AM Williams Laura A Chief Medical Officer May 23 '23 Sale 3.65 2,583 9,436 319,430 May 25 08:51 AM GRAMMER ELIZABETH A See Remarks May 23 '23 Sale 3.65 2,384 8,709 330,451 May 25 08:54 AM Felsch Robert Ora See Remarks May 23 '23 Sale 3.65 1,046 3,821 116,158 May 25 08:55 AM Rosenbaum David P. Chief Development Officer May 23 '23 Sale 3.65 934 3,412 112,162 May 25 08:52 AM
Index RUT P/E - EPS (ttm) -0.52 Insider Own 2.98% Shs Outstand 293.59M Perf Week 1.17%
Market Cap 3.08B Forward P/E 26.83 EPS next Y 0.39 Insider Trans -5.45% Shs Float 287.34M Perf Month -9.25%
Income -151.58M PEG - EPS next Q -0.06 Inst Own 106.28% Short Float 10.90% Perf Quarter -16.40%
Sales 399.36M P/S 7.71 EPS this Y 98.81% Inst Trans -4.29% Short Ratio 10.25 Perf Half Y -5.28%
Book/sh 0.55 P/B 19.06 EPS next Y 6481.79% ROA -20.18% Short Interest 31.32M Perf Year -13.76%
Cash/sh 0.97 P/C 10.76 EPS next 5Y - ROE -107.04% 52W Range 9.70 - 14.57 Perf YTD -26.71%
Dividend Est. - P/FCF - EPS past 5Y 22.84% ROI -25.39% 52W High -28.62% Beta 0.74
Dividend TTM - Quick Ratio 2.52 Sales past 5Y 37.81% Gross Margin 88.68% 52W Low 7.22% ATR (14) 0.37
Dividend Ex-Date - Current Ratio 2.88 EPS Y/Y TTM 37.05% Oper. Margin -18.40% RSI (14) 40.27 Volatility 3.64% 3.11%
Employees 517 Debt/Eq 2.78 Sales Y/Y TTM 21.30% Profit Margin -37.96% Recom 1.55 Target Price 18.78
Option/Short Yes / Yes LT Debt/Eq 2.73 EPS Q/Q 41.97% Payout - Rel Volume 0.45 Prev Close 10.43
Sales Surprise 0.64% EPS Surprise -90.31% Sales Q/Q 30.63% Earnings Feb 28 BMO Avg Volume 3.06M Price 10.40
SMA20 -3.06% SMA50 -10.67% SMA200 -14.42% Trades
Volume 1,379,209 Change -0.29%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-19-23 Upgrade Morgan Stanley
Equal-Weight → Overweight
$15 → $20
Sep-09-22 Initiated Morgan Stanley
Equal-Weight
$14
Apr-13-22 Resumed Goldman
Neutral
$11
Jan-14-22 Upgrade SVB Leerink
Mkt Perform → Outperform
$12 → $16
Nov-15-21 Upgrade Stifel
Hold → Buy
$12 → $16
Sep-30-21 Upgrade JP Morgan
Neutral → Overweight
$16
Jul-19-21 Resumed BTIG Research
Buy
$15
May-27-21 Initiated Needham
Hold
May-21-21 Initiated UBS
Buy
$16
Apr-14-21 Upgrade Cantor Fitzgerald
Neutral → Overweight
$17
Mar-02-21 Initiated Stifel
Hold
$13
Feb-12-21 Downgrade JP Morgan
Overweight → Neutral
$19
Feb-12-21 Downgrade Cantor Fitzgerald
Overweight → Neutral
$30 → $17
Dec-28-20 Resumed Cantor Fitzgerald
Overweight
$20 → $30
Dec-10-20 Downgrade Citigroup
Buy → Neutral
$20 → $27
Nov-11-20 Initiated Berenberg
Hold
Jun-17-20 Initiated BTIG Research
Buy
$19
Feb-04-20 Resumed Cantor Fitzgerald
Overweight
$19 → $20
Nov-12-19 Reiterated H.C. Wainwright
Buy
$18 → $20
Jun-17-19 Initiated H.C. Wainwright
Buy
$18
Show Previous Ratings
May-01-24 10:01AM
07:00AM
Mar-29-24 11:30AM
Mar-26-24 09:53AM
Mar-20-24 07:00AM
07:07AM
Loading…
Mar-13-24 07:07AM
Mar-06-24 11:56PM
Mar-05-24 01:50PM
(Investor's Business Daily)
Mar-01-24 07:00AM
Feb-29-24 11:25AM
11:23AM
Feb-28-24 11:49PM
(Thomson Reuters StreetEvents) -6.50%
08:20AM
07:32AM
07:00AM
07:00AM
Loading…
Feb-15-24 07:00AM
Feb-09-24 03:14PM
(Investor's Business Daily)
Feb-08-24 07:00AM
Feb-01-24 07:00AM
Jan-12-24 11:02PM
09:31AM
Jan-08-24 09:40AM
Jan-07-24 04:00PM
Jan-05-24 07:02PM
Jan-03-24 11:46AM
07:00AM
Dec-30-23 09:01AM
Dec-29-23 09:48AM
07:01AM
Dec-24-23 06:17AM
05:01AM
Loading…
Dec-21-23 05:01AM
Dec-08-23 11:30AM
Dec-05-23 06:38AM
06:00AM
05:30AM
(The Wall Street Journal)
Nov-15-23 09:48AM
Nov-10-23 10:07AM
Nov-09-23 01:02PM
Nov-08-23 07:13AM
(Associated Press Finance)
07:00AM
Nov-04-23 05:03AM
Nov-02-23 10:00AM
Nov-01-23 10:01AM
07:00AM
Oct-27-23 07:00AM
Oct-08-23 07:00AM
Oct-05-23 07:45PM
03:01AM
Oct-03-23 07:00AM
Oct-02-23 08:20AM
Oct-01-23 08:30PM
Sep-29-23 12:22PM
(Associated Press Finance)
09:09AM
Sep-28-23 11:08AM
10:50AM
10:41AM
10:32AM
(Investor's Business Daily)
Sep-21-23 08:42AM
Sep-07-23 11:30AM
Sep-01-23 07:00AM
Aug-29-23 07:00AM
Aug-21-23 07:00AM
Aug-15-23 07:00AM
Aug-09-23 09:25AM
Aug-08-23 08:40AM
07:29AM
07:00AM
Aug-07-23 08:48AM
Aug-04-23 08:05AM
Jul-31-23 07:00AM
Jul-23-23 10:23AM
Jul-20-23 02:24PM
(Investor's Business Daily)
Jul-17-23 01:54PM
(Investor's Business Daily)
Jun-28-23 10:53AM
Jun-27-23 07:00AM
Jun-09-23 11:30AM
Jun-04-23 09:59AM
May-11-23 07:44AM
May-10-23 08:15AM
07:10AM
07:00AM
May-08-23 10:00AM
May-02-23 07:00AM
May-01-23 10:01AM
07:00AM
Apr-26-23 01:00PM
Apr-18-23 09:20AM
Apr-14-23 02:45PM
Mar-31-23 11:30AM
Mar-27-23 07:00AM
Mar-08-23 07:00AM
Mar-02-23 11:39AM
04:28AM
(Thomson Reuters StreetEvents)
Mar-01-23 09:35AM
07:00AM
Feb-27-23 07:00AM
Feb-22-23 05:00PM
Feb-14-23 07:00AM
Feb-13-23 07:00AM
Feb-12-23 07:33AM
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Campbell Bradley L President and CEO May 01 '24 Option Exercise 8.61 7,500 64,575 894,154 May 03 05:21 PM Campbell Bradley L President and CEO May 01 '24 Sale 10.07 7,500 75,524 886,654 May 03 05:21 PM Campbell Bradley L President and CEO Apr 01 '24 Option Exercise 8.61 7,500 64,575 894,154 Apr 03 06:14 PM Campbell Bradley L President and CEO Apr 01 '24 Sale 11.67 7,500 87,496 886,654 Apr 03 06:14 PM SBLENDORIO GLENN Director Mar 07 '24 Option Exercise 2.80 15,000 42,000 83,596 Mar 11 05:36 PM RAAB MICHAEL Director Mar 05 '24 Option Exercise 2.80 15,000 42,000 83,596 Mar 06 05:22 PM MCGLYNN MARGARET G Director Mar 05 '24 Option Exercise 2.80 7,500 21,000 66,789 Mar 06 05:21 PM MCGLYNN MARGARET G Director Mar 05 '24 Sale 13.40 7,500 100,500 59,289 Mar 06 05:21 PM MCGLYNN MARGARET G Director Mar 04 '24 Option Exercise 2.80 7,500 21,000 66,789 Mar 06 05:21 PM MCGLYNN MARGARET G Director Mar 04 '24 Sale 13.29 7,500 99,675 59,289 Mar 06 05:21 PM Campbell Bradley L President and CEO Mar 01 '24 Option Exercise 10.54 15,833 166,904 887,052 Mar 05 05:14 PM Crowley John F Executive Chairman Mar 01 '24 Sale 13.35 29,181 389,543 573,478 Mar 05 05:14 PM Campbell Bradley L President and CEO Mar 01 '24 Sale 13.14 15,833 208,017 871,219 Mar 05 05:14 PM Crowley John F Executive Chairman Feb 15 '24 Sale 13.81 31,614 436,551 697,628 Feb 20 05:23 PM Clark David Michael Chief People Officer Feb 15 '24 Sale 14.00 4,427 61,978 253,664 Feb 20 05:20 PM Campbell Bradley L President and CEO Feb 15 '24 Sale 14.00 4,167 58,338 871,219 Feb 20 05:21 PM Rosenberg Ellen Chief Legal Officer Feb 07 '24 Option Exercise 5.16 29,600 152,736 397,254 Feb 08 04:40 PM Rosenberg Ellen Chief Legal Officer Feb 07 '24 Sale 13.00 29,600 384,818 367,654 Feb 08 04:40 PM Rosenberg Ellen Chief Legal Officer Feb 06 '24 Option Exercise 5.16 400 2,064 368,054 Feb 08 04:40 PM Rosenberg Ellen Chief Legal Officer Feb 06 '24 Sale 13.00 400 5,200 367,654 Feb 08 04:40 PM Campbell Bradley L President and CEO Feb 01 '24 Option Exercise 10.54 15,833 166,904 891,219 Feb 05 07:22 PM Crowley John F Executive Chairman Feb 01 '24 Sale 12.62 31,614 398,918 750,838 Feb 05 07:22 PM Campbell Bradley L President and CEO Feb 01 '24 Sale 12.56 15,833 198,858 875,386 Feb 05 07:22 PM Crowley John F Executive Chairman Jan 22 '24 Sale 12.36 55,327 683,958 782,452 Jan 24 05:20 PM Crowley John F Executive Chairman Jan 16 '24 Sale 12.78 31,614 404,106 837,779 Jan 18 05:09 PM Crowley John F Executive Chairman Jan 10 '24 Sale 13.65 31,614 431,452 869,393 Jan 11 06:33 PM Clark David Michael Chief People Officer Jan 09 '24 Sale 14.00 1,384 19,376 266,705 Jan 09 06:08 PM Prout Samantha Chief Accounting Officer Jan 09 '24 Sale 14.00 1,337 18,718 80,953 Jan 09 06:07 PM Prout Samantha Chief Accounting Officer Jan 08 '24 Sale 14.00 30,767 430,827 82,290 Jan 09 06:07 PM Clark David Michael Chief People Officer Jan 08 '24 Sale 14.00 8,726 122,164 268,089 Jan 09 06:08 PM Campbell Bradley L President and CEO Jan 02 '24 Option Exercise 10.54 15,833 166,904 956,138 Jan 04 06:35 PM Rosenberg Ellen Chief Legal Officer Jan 02 '24 Option Exercise 5.16 30,000 154,800 372,285 Jan 04 06:24 PM Rosenberg Ellen Chief Legal Officer Jan 02 '24 Sale 14.21 30,000 426,219 342,285 Jan 04 06:24 PM Campbell Bradley L President and CEO Jan 02 '24 Sale 14.23 15,833 225,380 947,805 Jan 04 06:35 PM Castelli Jeff Chief Development Officer Dec 28 '23 Sale 14.52 17,421 252,902 340,661 Dec 29 05:18 PM Rosenberg Ellen Chief Legal Officer Dec 27 '23 Option Exercise 5.16 5,000 25,800 347,285 Dec 28 05:08 PM Rosenberg Ellen Chief Legal Officer Dec 27 '23 Sale 14.07 5,000 70,327 342,285 Dec 28 05:08 PM Rosenberg Ellen Chief Legal Officer Dec 26 '23 Option Exercise 5.16 30,000 154,800 372,285 Dec 28 05:08 PM Rosenberg Ellen Chief Legal Officer Dec 26 '23 Sale 14.00 30,000 420,084 342,285 Dec 28 05:08 PM Prout Samantha Chief Accounting Officer Dec 26 '23 Sale 14.00 7,659 107,228 121,912 Dec 28 05:09 PM Castelli Jeff Chief Development Officer Dec 20 '23 Sale 13.10 1,654 21,667 358,082 Dec 20 04:41 PM Castelli Jeff Chief Development Officer Dec 19 '23 Sale 13.25 17,500 231,875 359,736 Dec 20 04:41 PM Crowley John F Executive Chairman Dec 15 '23 Sale 12.66 6,043 76,516 877,748 Dec 19 05:55 PM Campbell Bradley L President and CEO Dec 01 '23 Option Exercise 2.94 11,702 34,404 803,863 Dec 05 05:07 PM Campbell Bradley L President and CEO Dec 01 '23 Sale 11.08 11,702 129,693 792,161 Dec 05 05:07 PM Crowley John F Executive Chairman Dec 01 '23 Sale 11.08 6,043 66,956 883,791 Dec 05 05:03 PM Crowley John F Executive Chairman Nov 15 '23 Sale 10.84 6,043 65,497 889,834 Nov 17 05:23 PM Campbell Bradley L President and CEO Nov 01 '23 Option Exercise 2.94 11,700 34,398 803,861 Nov 03 07:38 PM Campbell Bradley L President and CEO Nov 01 '23 Sale 10.97 11,700 128,391 792,161 Nov 03 07:38 PM Crowley John F Executive Chairman Nov 01 '23 Sale 10.97 6,044 66,327 895,877 Nov 03 07:37 PM Crowley John F Executive Chairman Oct 16 '23 Sale 10.50 6,044 63,449 901,921 Oct 18 07:57 PM Campbell Bradley L President & CEO Oct 02 '23 Option Exercise 2.94 11,700 34,398 803,861 Oct 04 06:57 PM Campbell Bradley L President & CEO Oct 02 '23 Sale 11.24 11,700 131,489 792,161 Oct 04 06:57 PM Crowley John F Executive Chairman Oct 02 '23 Sale 11.25 6,044 67,967 907,965 Oct 04 06:58 PM Crowley John F Executive Chairman Sep 15 '23 Sale 13.06 6,044 78,964 914,009 Sep 18 05:09 PM Campbell Bradley L President & CEO Sep 01 '23 Option Exercise 2.94 11,700 34,398 810,254 Sep 06 05:29 PM Campbell Bradley L President & CEO Sep 01 '23 Sale 12.97 18,093 234,648 792,161 Sep 06 05:29 PM Crowley John F Executive Chairman Sep 01 '23 Sale 12.98 6,044 78,447 920,053 Sep 06 05:31 PM Crowley John F Executive Chairman Aug 15 '23 Sale 13.03 6,044 78,734 926,097 Aug 16 05:33 PM Prout Samantha Chief Accounting Officer Aug 09 '23 Option Exercise 11.03 36,909 407,116 173,912 Aug 11 05:28 PM Prout Samantha Chief Accounting Officer Aug 09 '23 Sale 14.01 36,909 516,933 137,003 Aug 11 05:28 PM Campbell Bradley L President & CEO Aug 01 '23 Option Exercise 2.94 11,700 34,398 818,554 Aug 03 05:09 PM Campbell Bradley L President & CEO Aug 01 '23 Sale 13.39 20,000 267,874 798,554 Aug 03 05:09 PM Crowley John F Executive Chairman Aug 01 '23 Sale 13.35 6,044 80,716 932,141 Aug 03 05:10 PM Crowley John F Executive Chairman Jul 17 '23 Sale 13.45 6,044 81,263 938,185 Jul 19 05:45 PM Campbell Bradley L President & CEO Jul 13 '23 Sale 12.51 6,800 85,091 806,854 Jul 14 05:06 PM Campbell Bradley L President & CEO Jul 12 '23 Sale 12.51 1,500 18,759 813,654 Jul 14 05:06 PM Campbell Bradley L President & CEO Jul 03 '23 Option Exercise 2.94 11,700 34,398 826,854 Jul 06 06:25 PM Campbell Bradley L President & CEO Jul 03 '23 Sale 12.31 11,700 144,016 815,154 Jul 06 06:25 PM Crowley John F Executive Chairman Jul 03 '23 Sale 12.31 6,044 74,406 944,229 Jul 06 06:26 PM Crowley John F Executive Chairman Jun 15 '23 Sale 13.04 6,044 78,814 950,273 Jun 20 05:18 PM Campbell Bradley L President & CEO Jun 06 '23 Sale 12.50 8,300 103,777 815,154 Jun 08 05:26 PM Campbell Bradley L President & CEO Jun 01 '23 Option Exercise 2.64 11,700 30,907 835,154 Jun 05 07:16 PM Campbell Bradley L President & CEO Jun 01 '23 Sale 11.36 11,700 132,942 823,454 Jun 05 07:16 PM Crowley John F Executive Chairman Jun 01 '23 Sale 11.36 6,044 68,657 956,317 Jun 05 07:16 PM SBLENDORIO GLENN Director May 18 '23 Option Exercise 3.32 15,000 49,800 86,719 May 19 05:13 PM Crowley John F Executive Chairman May 15 '23 Sale 11.18 6,044 67,577 962,361 May 17 06:20 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
